Page 103 - 南京医科大学学报自然科学版
P. 103

第44卷第2期      姚晓晨,张朋俊,陈正国,等. 国产无载体镥[ Lu]的制备及标记DOTA⁃TOC在神经内分泌肿瘤中的
                                                               177
                  2024年2月             初步临床应用探讨[J]. 南京医科大学学报(自然科学版),2024,44(2):235-241                   ·241 ·

                                                                                            177
                    Eur J Nucl Med Mol Imaging,2021,48(3):913-923      analogues on the uptake of[ Lu]Lu ⁃ HA ⁃ DOTATATE
               [6] KESAVAN M,GROVER P,LAM W,et al. Long⁃term he⁃      [J]. Eur J Nucl Med Mol Imaging,2023,50(5):1434-
                    matologic toxicity of  177 Lu⁃octreotate⁃capecitabine⁃temo⁃  1441
                    zolomide therapy of GEPNET[J]. Endocr Relat Cancer,  [12] BRABANDER T,VAN DER ZWAN W A,TEUNISSEN J
                                                                                                             177
                    2021,28(7):521-527                                 J M,et al. Long⁃term efficacy,survival,and safety of[ Lu
                                                                            0   3
               [7] PARGHANE R V,BHANDARE M,CHAUDHARI V,et              ⁃DOTA ,Tyr]octreotate in patients with gastroenteropan⁃
                    al. Surgical feasibility,determinants,and overall efficacy  creatic and bronchial neuroendocrine tumors[J]. Clin
                    of neoadjuvant  177 Lu ⁃ DOTATATE PRRT for locally ad⁃  Cancer Res,2017,23(16):4617-4624
                    vanced unresectable gastroenteropancreatic neuroendo⁃  [13] DEL PRETE M,BUTEAU F A,ARSENAULT F,et al.
                                                                                177
                    crine tumors[J]. J Nucl Med,2021,62(11):1558-      Personalized  Lu ⁃ octreotate peptide receptor radionu⁃
                    1563                                               clide therapy of neuroendocrine tumours:initial results
               [8] CHAHID Y,HASHIMI K,VAN DE GARDE E M W,et            from the P⁃PRRT trial[J]. Eur J Nucl Med Mol Imaging,
                    al. The influence of long⁃acting somatostatin analogs on  2019,46(3):728-742
                    68
                     Ga⁃DOTATATE uptake in patients with neuroendocrine  [14] ROLLEMAN E J,DE JONG M,VALKEMA R,et al. Inhi⁃
                    tumors[J]. Clin Nucl Med,2023,48(9):757-762        bition of kidney uptake of radiolabeled somatostatin ana⁃
               [9] AALBERSBERG E A,DE WIT ⁃ VAN DER VEEN B J,          logs:amino acids or gelofusine?[J]. J Nucl Med,2006,47
                    VERSLEIJEN M W J,et al. Influence of lanreotide on up⁃  (10):1730-1731
                          68
                    take of Ga⁃DOTATATE in patients with neuroendocrine  [15] 姚晓晨,张  川,臧士明,等. 肽受体放射性核素治疗
                    tumours:a prospective intra⁃patient evaluation[J]. Eur J  转移性神经内分泌肿瘤的效果和安全性[J]. 中华医学
                    Nucl Med Mol Imaging,2019,46(3):696-703            杂志,2022,102(14):1034-1038
               [10] HOPE T A,ALLEN ⁃ AUERBACH M,BODEI L,et al.   [16] ROLLEMAN E J,MELIS M,VALKEMA R,et al. Kidney
                    SNMMI procedure standard/EANM practice guideline for  protection during peptide receptor radionuclide therapy
                    SSTR PET:imaging neuroendocrine tumors[J]. J Nucl  with somatostatin analogues[J]. Eur J Nucl Med Mol Im⁃
                    Med,2023,64(2):204-210                             aging,2010,37(5):1018-1031
               [11] VEERMAN C H A M,SIEBINGA H,DE VRIES⁃HUIZ⁃                              [收稿日期] 2023-10-29
                    ING D M V,et al. The effect of long⁃acting somatostatin                     (本文编辑:唐      震)
   98   99   100   101   102   103   104   105   106   107   108